面对供应过剩、价格战以及欧盟、印度、巴基斯坦和巴西等主要出口市场日益增长的保护主义威胁，中国领先的光伏出口商——包括天合光能、隆基绿能和通威股份——承诺停止在海外市场的价格下调竞争。这一举措旨在稳定出口市场，推动行业可持续发展。 主要动态 行业协作： 由 中国机电产品进出口商会 牵头成立了由 22家光伏企业 组成的“自律”委员会，致力于促进健康竞争，稳定出口价格。 政策调整： 自 12月1日 起，硅片、电池片和组件的出口退税率将从 13% 降至 9% ，旨在鼓励出口高附加值产品，减少反倾销调查风险。 产能过剩危机： 过度生产导致价格下滑，造成大量亏损、裁员，甚至企业破产，给中国光伏企业带来沉重压力。 全球影响： 中国在光伏出口市场的主导地位受到越来越多的关注，外国市场可能采取反补贴措施，这为行业增加了更多的不确定性。 专家观点 大和证券分析师Dennis Ip： 退税率下调可能对光伏组件公司的短期财务状况产生负面影响，但从长期来看影响有限。 隆基绿能的观点： 行业领导者认为，这一举措是中国光伏行业的“转折点”，强调合作对于维持全球竞争力的重要性。 展望 随着中国光伏企业努力实现市场稳定，向高附加值产品和合作战略的转型有望改善行业的全球形象和长期韧性。然而， 产能过剩 和 退税减少 的直接挑战依然严峻。在国际市场压力下，如何平衡短期财务影响与长期发展需求，将成为行业关键议题
Amgen’s stock fell sharply in premarket trading, dropping 7.7% to $271.48, despite positive results from its Phase 2 study of experimental weight-loss drug MariTide.
Promising Data from MariTide Study
Amgen’s statement highlighted encouraging results from the 52-week study:
- Non-diabetic participants:Achieved an average 20% weight loss, with no plateau observed, suggesting potential for continued weight reduction beyond one year.
- Participants with Type 2 diabetes:Reported an average 17% weight loss over the same period.
The study involved nearly 600 adults living with obesity or overweight, showcasing MariTide’s potential as a competitive player in the weight-loss drug market.
Stock Reaction and Market Context
Despite the promising data, Amgen shares dropped 7.7% in premarket trading, marking the stock’s largest one-day percentage decline in over four years, according to Dow Jones Market Data.
In contrast, rival pharmaceutical companies gained ground:
- Novo Nordisk (NVO): Shares rose 2.1%.
- Eli Lilly (LLY): Shares climbed 4.5%.
The decline in Amgen’s stock suggests investor concerns about competition in the highly lucrative weight-loss drug market, where Novo Nordisk and Eli Lilly currently dominate with drugs like Wegovy and Mounjaro.
Government Policy Boosts Competitor Optimism
Adding to market dynamics, the Biden Administration announced plans on Tuesday to expand Medicare and Medicaid coverage for anti-obesity medications, further bolstering optimism for established players like Novo Nordisk and Eli Lilly.
Takeaway
While Amgen’s MariTide results highlight potential breakthroughs in weight-loss treatment, the stock’s decline underscores competitive pressure and investor caution in a rapidly evolving market. With government policies set to expand access to weight-loss drugs, the stakes are higher than ever for pharmaceutical companies vying for dominance.
Comments
Post a Comment